Clinical Trials

View All Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

No search term entered. 352 results shown below.

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

[Complete title: HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning with Low-dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2032.00
Phase: II

Nonmyeloablative transplant for severe systemic sclerosis

[Complete title: Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2067.00
Phase: I/II

Gene Therapy for Fanconi Anemia

[Complete title: Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 2097.00
Phase: I

Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

[Complete title: Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2256.00
Phase: II

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

[Complete title: Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2368.00
Phase: NA

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

[Complete title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 2398.00
Phase: II

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2430.00
Phase: II

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

[Complete title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)]
Principal Investigator: Edward Libby
Study Number: 2477.00
Phase: III

Scleroderma Treatment with Autologous Transplant (STAT) Study

[Complete title: A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2533.00
Phase: II

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

[Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies]
Principal Investigator: Filippo Milano
Study Number: 2603.00
Phase: II

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

[Complete title: Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion with Cyclophosphamide and Fludarabine For Patients With Metastatic Melanoma]
Principal Investigator: Sylvia Lee, MD
Study Number: 2643.00
Phase: II

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

[Complete title: Initial Cytoreductive Therapy for Myelodysplastic Syndrome prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)]
Principal Investigator: Bart Scott, MD
Study Number: 2661.00
Phase: II

Abatacept as GVHD Prophylaxis Phase 2

[Complete title: Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial]
Principal Investigator: Leslie Kean
Study Number: 2692.00
Phase: II

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

[Complete title: A Pilot Study to Test whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients with Synovial Sarcoma and Myxoid / Round Cell Liposarcoma]
Principal Investigator: Seth Pollack
Study Number: 2705.00
Phase: Pilot

Chronic GVHD Response Measures Validation

[Complete title: Chronic GVHD Response Measures Validation]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2710.00
Phase: NA

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)]
Principal Investigator: Roland Walter, MD
Study Number: 2734.00
Phase: I/II

Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms

[Complete title: Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study]
Principal Investigator: Heidi Gray, MD
Study Number: 7750
Phase: Pilot

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

[Complete title: A Phase II Study of Weekly ABRAXANE® for Patients with Advanced NSCLC with EGFR Mutations or with Durable Response to an EGFR Tyrosine Kinase Inhibitor following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors]
Principal Investigator: Christina Baik
Study Number: 7755
Phase: II

Cabozantinib in Treating Men With Hormone-Resistant Prostate Cancer

[Complete title: A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 7819
Phase: Pilot

Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

[Complete title: Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently with a HER2 ICD Peptide-Based Vaccine in Patients with Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy]
Principal Investigator: Lupe Salazar, MD
Study Number: 7866
Phase: I/II

Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

[Complete title: Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 7910
Phase: Pilot

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

[Complete title: NU 11I03: A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)]
Principal Investigator: Gabriela Chiorean
Study Number: 8007
Phase: I/II

CYT107 After Vaccine Treatment (Provenge) in Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)]
Principal Investigator: Evan Yu, MD
Study Number: 8037A
Phase: II

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

[Complete title: Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)]
Principal Investigator: Hannah Linden, MD
Study Number: 8093
Phase: II

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

[Complete title: MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix]
Principal Investigator: Nina Mayr, MD
Study Number: 8118
Phase: NA

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy (ITOMIC)

[Complete title: Intensive Trial of OMics in Cancer (ITOMIC) 001- Intensive Longitudinal Monitoring in Subjects with Triple Negative Breast Cancer]
Principal Investigator: Tony Blau, MD
Study Number: 8132
Phase: Pilot

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy

[Complete title: Pulmonary Functional Imaging for Radiation Treatment Planning]
Principal Investigator: Jing Zeng
Study Number: 8180
Phase: Pilot

Web-Delivered Acceptance & Commitment Therapy for Smokers With Bipolar Disorder (WebQuit Plus)

[Complete title: Web-Delivered Acceptance & Commitment Therapy for Smokers with Bipolar Disorder]
Principal Investigator: Jaimee Heffner
Study Number: 8363

Together We STRIDE (Strategizing Together Relevant Interventions for Diet and Exercise)

[Complete title: Together We STRIDE]
Principal Investigator: Linda Ko
Study Number: 8417
Phase: II

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

[Complete title: A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 9023
Phase: II

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

[Complete title: RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy followed by Ipilimumab in Metastatic Melanoma]
Principal Investigator: Ramesh Rengan
Study Number: 9031
Phase: II

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

[Complete title: JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study]
Principal Investigator: Rachel Salit
Study Number: 9033
Phase: II

Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling

[Complete title: Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) with Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing]
Principal Investigator: Robert Montgomery, MD
Study Number: 9055
Phase: II

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

[Complete title: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients with Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)]
Principal Investigator: Ajay Gopal, MD
Study Number: 9111
Phase: I/II

Allo vs. Hypomethylating/Best Supportive Care in MDS

[Complete title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome]
Principal Investigator: Bart Scott, MD
Study Number: 9129
Phase: III

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

[Complete title: A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients]
Principal Investigator: Nora Disis, MD
Study Number: 9140
Phase: I

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

[Complete title: A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) with Radiation in Patients with Metastatic Sarcoma]
Principal Investigator: Seth Pollack
Study Number: 9145
Phase: I

Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy

[Complete title: Definitive Re-Irradiation with Proton Beam Radiotherapy for Patients with Recurrent Thoracic Cancers]
Principal Investigator: Jing Zeng
Study Number: 9148
Phase: Pilot

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

[Complete title: Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)]
Principal Investigator: K.Scott Baker
Study Number: 9161
Phase: II

WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

[Complete title: A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin Prior to Surgery in Squamous Cell Carcinoma of the Head and Neck (HNSCC)]
Principal Investigator: Eddie Mendez
Study Number: 9168
Phase: I

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

[Complete title: Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer]
Principal Investigator: Eddie Mendez
Study Number: 9188
Phase: II

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

[Complete title: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 9198
Phase: II

Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

[Complete title: Prevention of Bone Loss after Pediatric Hematopoietic Cell Transplantation]
Principal Investigator: K.Scott Baker
Study Number: 9223
Phase: II

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

[Complete title: Carfilzomib for Treatment of Chronic Graft-versus-Host Disease]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 9228
Phase: II

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

[Complete title: A Phase II Multicenter Randomized Trial Evaluating 3-year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer treated with Chemoradiation plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management]
Principal Investigator: Andrew Coveler, MD
Study Number: 9240
Phase: II

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

[Complete title: Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination with MHC Class I Up-regulation and the Anti-PD-L1 Antibody Avelumab]
Principal Investigator: Aude Chapuis, MD
Study Number: 9245
Phase: I/II

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

[Complete title: Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy after Autologous Transplant for Treating Multiple Myeloma]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 9266
Phase: II

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

[Complete title: Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy]
Principal Investigator: Jonathan Wright
Study Number: 9274
Phase: II/III

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer

[Complete title: A Phase I/II Trial of Concurrent Chemohormonal therapy using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer]
Principal Investigator: Heather Cheng
Study Number: 9279
Phase: I/II

Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer

[Complete title: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer]
Principal Investigator: Heidi Gray, MD
Study Number: 9288
Phase: II/III

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

[Complete title: MK-3475 in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma]
Principal Investigator: Stephen Smith
Study Number: 9291
Phase: II

Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

[Complete title: Ixazomib for Treatment of Chronic Graft-versus-Host Disease]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 9292
Phase: II

Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer

[Complete title: A Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men with Metastatic Prostate Cancer]
Principal Investigator: Michael Schweizer
Study Number: 9297
Phase: Pilot

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL)

[Complete title: PARTIQol: Prostate Advance Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer]
Principal Investigator: Jing Zeng
Study Number: 9328
Phase: III

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

[Complete title: Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide]
Principal Investigator: Ajay Gopal, MD
Study Number: 9340
Phase: Pilot

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance (Transformer)

[Complete title: A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)]
Principal Investigator: Michael Schweizer
Study Number: 9342
Phase: II

Diet and Exercise Program in Promoting Weight Loss and Improving Health in Patients With Low- or Low-Intermediate-Risk Prostate Cancer (PALS)

[Complete title: PALS: Prostate Cancer Active Lifestyle Study]
Principal Investigator: Jonathan Wright
Study Number: 9369
Phase: NA

Docetaxel and Carboplatin in Treating Patients With Metastatic, Hormone Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

[Complete title: A Pilot Study of Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway]
Principal Investigator: Heather Cheng
Study Number: 9381
Phase: Pilot

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer: (Rapamycin inhibition of DDSP (RID)]
Principal Investigator: Robert Montgomery, MD
Study Number: 9388
Phase: I/II

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

[Complete title: A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients with Metastatic Prostate Cancer]
Principal Investigator: Michael Schweizer
Study Number: 9389
Phase: I

Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

[Complete title: A Phase I Study of Niclosamide in Combination with Enzalutamide in Men with Castration-Resistant Prostate Cancer]
Principal Investigator: Michael Schweizer
Study Number: 9390
Phase: I

Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors

[Complete title: Developing an Intervention to Reduce Stress and Improve Quality of Life in Underserved Urban Latina Breast Cancer Survivors]
Principal Investigator: Rachel Ceballos
Study Number: 9425
Phase: NA

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

[Complete title: A Phase 1b study of JCAR014, autologous T cells engineered to express a CD19-specific chimeric antigen receptor, in combination with durvalumab (MEDI4736) for relapsed/refractory B-cell non-Hodgkin lymphoma]
Principal Investigator: Cameron Turtle, PhD, MBBS
Study Number: 9457
Phase: I

Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

[Complete title: A Phase II Study of Anti-PD-1 Antibody (MK-3475; pembrolizumab) for the Treatment of Minimal Residual Disease in Adults with Acute Lymphoblastic Leukemia]
Principal Investigator: Ryan Cassaday
Study Number: 9458
Phase: II

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

[Complete title: Multicenter Phase II, Double-Blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 9464
Phase: II

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

[Complete title: Continued, Long-Term Follow-up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 9485
Phase: III

A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC

[Complete title: A Pilot Study of MPDL3280A (PD-L1 Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients with Metastatic Non-Small Cell Lung Cancer (UMCC 2015.005)]
Principal Investigator: Ramesh Rengan
Study Number: 9490
Phase: Pilot

Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease

[Complete title: Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft vs. Host Disease]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 9514
Phase: II

Tethered Capsule Endoscope in Screening Patients With Barrett Esophagus

[Complete title: Tethered Capsule Endoscope in Screening for Barrett's Esophagus - A Pilot Study]
Principal Investigator: Michael Saunders, MD
Study Number: 9561
Phase: Pilot

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia

[Complete title: A Feasibility Study of “Early” Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory AML]
Principal Investigator: Mary-Elizabeth Percival
Study Number: 9567
Phase: Pilot

Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

[Complete title: Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes]
Principal Investigator: Ann Woolfrey, MD
Study Number: 9577
Phase: Pilot

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

[Complete title: Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell (DC)/Myeloma Fusions]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 9580
Phase: II

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

[Complete title: Personalized Radiation Therapy through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)]
Principal Investigator: Jing Zeng
Study Number: 9599
Phase: II

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

[Complete title: A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients with Advanced Stage Non-small Cell Lung Cancer that have Progressed through First Line Platinum Doublet Chemotherapy]
Principal Investigator: Rafael Santana-Davila
Study Number: 9602
Phase: I/II

Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery

[Complete title: A Trial of Pembrolizumab in Combination with Doxorubicin as Treatment for Patients with Advanced Sarcomas]
Principal Investigator: Seth Pollack
Study Number: 9624
Phase: I/II

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (WOKVAC)

[Complete title: A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients with Breast Cancer]
Principal Investigator: Nora Disis, MD
Study Number: 9626
Phase: I

Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

[Complete title: Phase I study of neo-adjuvant RO7009789 alone or neo-adjuvant RO7009789 plus nab-paclitaxel and gemcitabine followed by adjuvant RO7009789 plus nab-paclitaxel and gemcitabine for patients with newly diagnosed resectable pancreatic carcinoma]
Principal Investigator: Gabriela Chiorean
Study Number: 9627
Phase: I

A Phase II neoadjuvant study of ARN-509, abiraterone acetate, prednisone, degarelix and indomethacin in men with localized prostate cancer pre- prostatectomy

[Complete title: A Phase II neoadjuvant study of ARN-509, abiraterone acetate, prednisone, degarelix and indomethacin in men with localized prostate cancer pre- prostatectomy]
Principal Investigator: Michael Schweizer
Study Number: 9628
Phase: II

Cisplatin vs Paclitaxel for Triple Neg

[Complete title: A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker]
Principal Investigator: Jennifer Specht, MD
Study Number: 9641
Phase: II

Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

[Complete title: Functional Liver Imaging with Sulfur Colloid SPECT/CT in Primary and Metastatic Liver Cancer Patients Receiving Liver-Directed Treatment: A Pilot Study]
Principal Investigator: Smith Apisarnthanarax
Study Number: 9646
Phase: Pilot

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

[Complete title: A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease]
Principal Investigator: Marco Mielcarek, MD
Study Number: 9710
Phase: II

Endocrine Response in Women With Invasive Lobular Breast Cancer

[Complete title: A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer]
Principal Investigator: Hannah Linden, MD
Study Number: 9743
Phase: II

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

[Complete title: Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults with Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study]
Principal Investigator: Anna Halpern
Study Number: 9759
Phase: I

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

[Complete title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy]
Principal Investigator: Janice Kim, MD
Study Number: A011202
Phase: III

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE)

[Complete title: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy]
Principal Investigator: Larissa Korde
Study Number: A221405
Phase: NA

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma

[Complete title: ACNS0332, Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS0332
Phase: III

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

[Complete title: Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: (see comment for full title)]
Principal Investigator: Julie Park, MD
Study Number: ENCIT-01
Phase: I

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

[Complete title: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy]
Principal Investigator: Heidi Gray, MD
Study Number: GOG 0724/ RTOG 0724
Phase: III

Health Effects After Leukemia Research Study #2 (HEAL-2)
Principal Investigator: Eric Chow, MD
Study Number: HEAL-2
Phase: NA

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat (N2011-01)

[Complete title: NANT 2011-01: STUDY OF SINGLE-AGENT 131I-MIBG, 131I-MIBG WITH VINCRISTINE AND IRINOTECAN, OR 131I-MIBG WITH VORINOSTAT FOR RESITANT/RELAPSED NEUROBLASTOMA]
Principal Investigator: Julie Park, MD
Study Number: NANT 2011-01
Phase: II

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

[Complete title: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia]
Principal Investigator: Rebecca Gardner, MD
Study Number: PLAT-02
Phase: I/II

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia (Interfant06)

[Complete title: SC-2006. Interfant 06, International Collaborative Treatment Protocol For Infants Under One Year with Acute Lymphoblastic Leukemia or Biphenotypic Leukemia]
Principal Investigator: Rebecca Gardner, MD
Study Number: SC-2006
Phase: III

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (CRAD001NUS175T)

[Complete title: SC-2015, A Feasibility trial of everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction in patients with relapsed acute lymphoblastic leukemia (ALL)]
Principal Investigator: Todd Cooper
Study Number: SC-2015
Phase: I

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

[Complete title: SC-2025, Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML]
Principal Investigator: Todd Cooper
Study Number: SC-2025
Phase: I

Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

[Complete title: SC-4002, An Open Label, Expanded Access Protocol Using 131I - Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma]
Principal Investigator: Julie Park, MD
Study Number: SC-4002

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma

[Complete title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib, and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: SC-6015
Phase: I

A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis

[Complete title: A Pilot Study Evaluating the use of the mTOR Inhibitor Sirolimus in Children and Young Adults with Desmoid-Type Fibromatosis]
Principal Investigator: Doug Hawkins, MD
Study Number: SC-6016
Phase: Pilot

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

[Complete title: SC-9002: A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paciltaxel, and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoeitic Stem Cell Rescue (AuHSCR) for patients with…]
Principal Investigator: Sarah Leary
Study Number: SC-9002
Phase: II

Construction of a Metastatic Osteosarcoma Tissue Microarray
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B604

Evaluation of microRNAs as novel markers of cardiotoxicity in children undergoing anthracycline therapy for pediatric cancer
Principal Investigator: Kasey Leger, MD
Study Number: SC-B610

Genetic Risk Factors of Ewing Sarcoma
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B611

Exploring Genetic Changes In Pediatric Brain Tumors
Principal Investigator: Sarah Leary
Study Number: SC-B904

Decision-making for the child with relapsed or refractory neuroblastoma
Principal Investigator: Abby Rosenberg
Study Number: SC-N110

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Ann Dahlberg
Study Number: 2010.00
Phase: II

A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

[Complete title: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas]
Principal Investigator: Elizabeth Loggers
Study Number: 20132286
Phase: II

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2206.00
Phase: II

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

[Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2241.00
Phase: II

Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

[Complete title: High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases]
Principal Investigator: George Georges, MD
Study Number: 2260.00
Phase: II

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Filippo Milano
Study Number: 2275.00
Phase: II

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source]
Principal Investigator: Rachel Salit
Study Number: 2372.00
Phase: II

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

[Complete title: A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2468.00
Phase: I

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

[Complete title: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2531.00
Phase: NA

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2546.00
Phase: II

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

[Complete title: A Phase II, Non-Randomized, Single Institution, Clinical Trial of Signal Transduction Inhibitors, Ibrutinib or Idelalisib, To Treat Patients with Persistent or relapsed B-cell Malignancies Following Allogeneic Hematopoietic Cell Transplantation]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2561.00
Phase: II

Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)

[Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies]
Principal Investigator: Rachel Salit
Study Number: 2580.00
Phase: III

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

[Complete title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor]
Principal Investigator: David Maloney, MD, PhD
Study Number: 2639.00
Phase: I/II

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

[Complete title: A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction with Standard Chemotherapy for Treatment of Lymphoma in Patients with HIV Infection]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2673.00
Phase: I

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

[Complete title: A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD]
Principal Investigator: Marie Bleakley, MD
Study Number: 2684.00
Phase: II

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

[Complete title: Phase I/II Study in WT1-expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy with Polyclonal Autologous Central Memory to Naïve CD8+ T cells that have been Transduced to Express a WT1-specific T cell Receptor]
Principal Investigator: Sylvia Lee, MD
Study Number: 2727.00
Phase: I/II

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

[Complete title: A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2728.00
Phase: I/II

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

[Complete title: Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy]
Principal Investigator: Robert Montgomery, MD
Study Number: 6932
Phase: NA

Cognitive Rehabilitation in Cancer Survivors: A Pilot Study
Principal Investigator: Monique Cherrier, PhD
Study Number: 7279
Phase: NA

Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

[Complete title: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally - Advanced Resected Head and Neck Cancer]
Principal Investigator: George Laramore, MD, PhD
Study Number: 7428
Phase: III

Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma

[Complete title: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma]
Principal Investigator: George Laramore, MD, PhD
Study Number: 8078
Phase: III

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

[Complete title: Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination with Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers]
Principal Investigator: Gabriela Chiorean
Study Number: 9078
Phase: I

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

[Complete title: Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study]
Principal Investigator: Anna Halpern
Study Number: 9105
Phase: Pilot

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma

[Complete title: A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 9107
Phase: Pilot

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

[Complete title: Evaluation of Pretargeted anti-CD20 Radioimmunotherapy Combined with BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-cell Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 9189
Phase: I

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

[Complete title: A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine]
Principal Investigator: K.Scott Baker
Study Number: 9213
Phase: II

COcoa Supplement and Multivitamin Outcomes Study (COSMOS)

[Complete title: The Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) Trial Protocol]
Principal Investigator: Garnet Anderson, PhD
Study Number: 9214
Phase: NA

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

[Complete title: Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 9226
Phase: Pilot

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

[Complete title: A Single Arm Phase I/II Study of MK-3475 Combined with Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies]
Principal Investigator: Tina Rodriguez, MD
Study Number: 9383
Phase: I/II

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

[Complete title: A Phase II Study of Deferasirox in Patients with Red Blood Cell Transfusion Dependent Myelodysplastic Syndromes]
Principal Investigator: Bart Scott, MD
Study Number: 9422
Phase: II

Enhancing Connections Program in Improving Communication Between Patients With Incurable Cancer and Their Children

[Complete title: The Enhancing Connections Program in Palliative Care: Taking Care of the Children]
Principal Investigator: Frances Lewis, PhD
Study Number: 9480
Phase: Pilot

Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors

[Complete title: A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors]
Principal Investigator: Manoj Menon
Study Number: 9493
Phase: I

Filgrastim, Cladribine, Cytarabine and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

[Complete title: Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD status: A Phase 1/2 Study]
Principal Investigator: Anna Halpern
Study Number: 9510
Phase: I/II

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

[Complete title: A Window Study of Ixazomib in Untreated Indolent B-NHL]
Principal Investigator: Ajay Gopal, MD
Study Number: 9571
Phase: II

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

[Complete title: Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer (mCRC)]
Principal Investigator: Gabriela Chiorean
Study Number: 9578
Phase: II

Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma

[Complete title: A Phase 1 Study of Weekly Paclitaxel and Nortriptyline for Relapsed Small Cell Carcinoma]
Principal Investigator: Robert Montgomery, MD
Study Number: 9618
Phase: I

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

[Complete title: A Phase I/ II Study of chemo radiation plus the Anti-PD-1 Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma]
Principal Investigator: Tina Rodriguez, MD
Study Number: 9649
Phase: I/II

Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

[Complete title: Randomized Phase 1 Study of Sequential (“Primed”) vs. Concurrent Decitabine in Combination with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)]
Principal Investigator: Sarah Buckley
Study Number: 9713
Phase: I

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

[Complete title: A Phase II Randomized, Placebo -Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant]
Principal Investigator: Joshua Hill
Study Number: 9733
Phase: II

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

[Complete title: Anti-PD-1 Therapy in Combination with Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer]
Principal Investigator: John Liao
Study Number: 9740
Phase: I/II

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

[Complete title: A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults with Acute Lymphoblastic Leukemia/Lymphoma]
Principal Investigator: Ryan Cassaday
Study Number: 9770
Phase: II

Long Term Follow-Up of Patients Previously Entered on Children's Hospital and Regional Medical Center Hematology/Oncology Clinical Trials
Principal Investigator: K.Scott Baker
Study Number: CHMC-L001

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

[Complete title: Molecular Analysis for Therapy Choice (MATCH)]
Principal Investigator: Fred Appelbaum, MD
Study Number: EAY131
Phase: II

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

[Complete title: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer (GOG-0281)]
Principal Investigator: Heidi Gray, MD
Study Number: GOG-0281
Phase: II/III

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

[Complete title: Phase II Randomized Trial of Nivolumab with or Without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer]
Principal Investigator: Heidi Gray, MD
Study Number: NRG-GY003
Phase: II

Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

[Complete title: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer]
Principal Investigator: Heidi Gray, MD
Study Number: NRG-GY004
Phase: III

Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

[Complete title: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) [Phase II]]
Principal Investigator: Heidi Gray, MD
Study Number: NRG-GY005
Phase: II/III

PD-1 Pathway Protein Expression in Pediatric Cancer
Principal Investigator: Doug Hawkins, MD
Study Number: SC-B609

Prospective Blood Collection for Local Immunotherapy Pre-Clinical Studies
Principal Investigator: Rebecca Gardner, MD
Study Number: SC-B801

Computer Based Tool to Explore Symptom Clusters in Adolescents with Cancer
Principal Investigator: Catherine Macpherson, PhD, RN
Study Number: SC-N104
Phase: NA

Resilience in Serious Illness: a pilot feasibility study of the Promoting Resilience in Stress Management (PRISM) Intervention
Principal Investigator: Abby Rosenberg
Study Number: SC-N108

A Pilot RCT of the PRISM Intervention for AYAs With Cancer

[Complete title: A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults with Cancer]
Principal Investigator: Abby Rosenberg
Study Number: SC-N114
Phase: Pilot

PRISM for Parents of Children With Cancer Promoting Resilience in Stress Management (PRISM) Intervention for Parents of Children With Cancer

[Complete title: A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention in Parents of Children with Cancer]
Principal Investigator: Abby Rosenberg
Study Number: SC-N120
Phase: Pilot

Hypospadias, Indescended Testis, and Testicular Tumors: A Data and Specimen Banking Pilot Study
Principal Investigator: Margarett Shnorhavorian
Study Number: SCH-HUT-1

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

[Complete title: TACL 2014-001: A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.]
Principal Investigator: Todd Cooper
Study Number: TACL 2014-001
Phase: I

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

[Complete title: A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC)]
Principal Investigator: Paul Nghiem
Study Number: 8269a
Phase: II

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Melanoma

[Complete title: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Sarcoma, Colon, Non-Hodgkin Lymphoma, Non-Small Cell Lung, Squamous Cell Head and Neck Cancer and Cutaneous Squamous Cell Cancer]
Principal Investigator: Sylvia Lee, MD
Study Number: 9103A
Phase: I

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

[Complete title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: 9174
Phase: III

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

[Complete title: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer]
Principal Investigator: Heather Cheng
Study Number: 9293
Phase: III

Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

[Complete title: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision]
Principal Investigator: Gabriela Chiorean
Study Number: 9412
Phase: II/III

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

[Complete title: [F18] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer.]
Principal Investigator: Hannah Linden, MD
Study Number: 9594
Phase: II

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

[Complete title: Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial]
Principal Investigator: Li-Ming Fang
Study Number: 9701
Phase: III

Breast Cancer WEight Loss Study (BWEL Study)

[Complete title: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: A011401
Phase: III

Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

[Complete title: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial]
Principal Investigator: Julie Gralow, MD
Study Number: A011502
Phase: III

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

[Complete title: A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: A051301
Phase: III

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

[Complete title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Rafael Santana-Davila
Study Number: A081105
Phase: III

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

[Complete title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)]
Principal Investigator: Rafael Santana-Davila
Study Number: A151216
Phase: NA

Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

[Complete title: AALL05B1, A Children's Oncology Group Protocol for the Collecting and Banking of Relapsed Acute Lymphoblastic Leukemias]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL05B1

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

[Complete title: AALL08B1, Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL08B1

Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

[Complete title: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL).]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL0932
Phase: III

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

[Complete title: AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL1131
Phase: III

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

[Complete title: AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)]
Principal Investigator: Kasey Leger, MD
Study Number: AALL1231
Phase: III

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

[Complete title: AALL1331 Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)]
Principal Investigator: Rebecca Gardner, MD
Study Number: AALL1331
Phase: III

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

[Complete title: AALL1131, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.]
Principal Investigator: Doug Hawkins, MD
Study Number: AAML1031
Phase: III

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

[Complete title: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid]
Principal Investigator: Todd Cooper
Study Number: AAML1331
Phase: III

Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia]
Principal Investigator: Todd Cooper
Study Number: AAML1421
Phase: I/II

Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

[Complete title: ACCL0933, A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML).]
Principal Investigator: Doug Hawkins, MD
Study Number: ACCL0933
Phase: III

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

[Complete title: ACCL1033, A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL]
Principal Investigator: Eric Chow, MD
Study Number: ACCL1033
Phase: NA

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

[Complete title: ACCL1034, Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLA-BSI) and Acquisition of Multi-Drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic HCT]
Principal Investigator: Julie Park, MD
Study Number: ACCL1034
Phase: III

Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group

[Complete title: ACCRN07, Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) and Local Data Collection]
Principal Investigator: Doug Hawkins, MD
Study Number: ACCRN07

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

[Complete title: ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS0831
Phase: III

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

[Complete title: ADVL1212, A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)]
Principal Investigator: Julie Park, MD
Study Number: ADVL1212
Phase: I

WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

[Complete title: ADVL1217, A Phase 1 Study of MK-1775 (IND#116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas]
Principal Investigator: Julie Park, MD
Study Number: ADVL1217
Phase: I

WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

[Complete title: ADVL1312, A PHASE 1/2 STUDY OF MK-1775 (AZD1775, IND# 121422) IN COMBINATION WITH ORAL IRINOTECAN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SOLID TUMORS]
Principal Investigator: Julie Park, MD
Study Number: ADVL1312
Phase: I/II

BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

[Complete title: ADVL1411, PHASE 1/ 2 STUDY OF BMN 673 (IND# 121510), AN ORAL POLY(ADP-RIBOSE) POLYMERASE INHIBITOR, PLUS TEMOZOLOMIDE IN CHILDREN WITH REFRACTORY OR RECURRENT MALIGNANCIES]
Principal Investigator: Julie Park, MD
Study Number: ADVL1411
Phase: I/II

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

[Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab]
Principal Investigator: Julie Park, MD
Study Number: ADVL1412
Phase: I/II

Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

[Complete title: AEWS07B1, A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens]
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS07B1
Phase: NA

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

[Complete title: AEWS1221, Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS1221
Phase: II

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

[Complete title: AHEP0731, Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment]
Principal Investigator: Doug Hawkins, MD
Study Number: AHEP0731
Phase: III

Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma

[Complete title: AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents]
Principal Investigator: Doug Hawkins, MD
Study Number: AHOD1331
Phase: III

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

[Complete title: ALTE07C1, Neuropyschological, Social, Emotional and Behavioral Outcomes in Children with Cancer]
Principal Investigator: Doug Hawkins, MD
Study Number: ALTE07C1
Phase: NA

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

[Complete title: ANBL1221, A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND#61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory,Relapsed or Progressive Neuroblastoma]
Principal Investigator: Julie Park, MD
Study Number: ANBL1221

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

[Complete title: ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study]
Principal Investigator: Julie Park, MD
Study Number: ANBL1232
Phase: III

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

[Complete title: ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)]
Principal Investigator: Rebecca Gardner, MD
Study Number: ANHL12P1

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

[Complete title: Phase 2 Study of Denosumab, a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AOST1321
Phase: II

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

[Complete title: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)]
Principal Investigator: Doug Hawkins, MD
Study Number: ARST1321
Phase: II

A Single Arm Trial of Systemic and Subtenon Chemotherapy for Group C/D Intraocular Retinoblastoma
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARET0231
Phase: III

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

[Complete title: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer]
Principal Investigator: Hannah Linden, MD
Study Number: E2112
Phase: III

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

[Complete title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein]
Principal Investigator: Rafael Santana-Davila
Study Number: E4512
Phase: III

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

[Complete title: Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts]
Principal Investigator: Habib Rahbar
Study Number: EA1141
Phase: II

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL)

[Complete title: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers]
Principal Investigator: Rafael Santana-Davila
Study Number: EA5142
Phase: III

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

[Complete title: Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival?]
Principal Investigator: Heidi Gray, MD
Study Number: GOG 0225
Phase: III

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

[Complete title: NANT 2011-04: A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma]
Principal Investigator: Julie Park, MD
Study Number: NANT 2011-04
Phase: II

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

[Complete title: NANT 2012-01 PHASE I STUDY OF DIFLUOROMETHYLORNITHINE (DFMO) AND CELECOXIB WITH CYCLOPHOSPHAMIDE/TOPOTECAN FOR PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA]
Principal Investigator: Julie Park, MD
Study Number: NANT 2012-01
Phase: I

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

[Complete title: NANT 2014-01 Phase I Study of SF1126 for Patients with Relapsed or Refractory Neuroblastoma]
Principal Investigator: Julie Park, MD
Study Number: NANT 2014-01
Phase: I

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

[Complete title: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma]
Principal Investigator: Lia Halasz
Study Number: NRG-BN001
Phase: II

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

[Complete title: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy]
Principal Investigator: Janice Kim, MD
Study Number: NSABP B-51 / RTOG 1304
Phase: III

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

[Complete title: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy]
Principal Investigator: Jennifer Specht, MD
Study Number: NSABP B-55
Phase: III

Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas

[Complete title: Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E-or BRAF Ins T mutant gliomas]
Principal Investigator: Sarah Leary
Study Number: PNOC002
Phase: Pilot

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

[Complete title: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC]
Principal Investigator: Ramesh Rengan
Study Number: RTOG 1308
Phase: III

Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer

[Complete title: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer]
Principal Investigator: Christina Baik
Study Number: S1400
Phase: II/III

Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer

[Complete title: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: S1416
Phase: II

Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

[Complete title: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy]
Principal Investigator: Julie Gralow, MD
Study Number: S1418
Phase: III

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

[Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)]
Principal Investigator: Ajay Gopal, MD
Study Number: 20110654
Phase: I

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

[Complete title: A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)]
Principal Investigator: William Harris
Study Number: 20111617
Phase: III

A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

[Complete title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS 9973 in Subjects with Relapsed or Refractory Hematologic Malignancies]
Principal Investigator: Andrei Shustov, MD
Study Number: 20122094
Phase: II

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

[Complete title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib]
Principal Investigator: William Harris
Study Number: 20130857
Phase: III

A Safety Study of SGN-LIV1A in Breast Cancer Patients

[Complete title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 20131069
Phase: I

AZD8186 First Time In Patient Ascending Dose Study

[Complete title: A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB Mutated Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186]
Principal Investigator: Tia Higano, MD
Study Number: 20131275
Phase: I

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

[Complete title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumor]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20131294
Phase: I

MSB0010718C in Solid Tumors

[Complete title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications]
Principal Investigator: Nora Disis, MD
Study Number: 20132079
Phase: I

An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

[Complete title: An Open-Label, Extension (Rollover) Study Of Vemurafenib in Patients with BRAFV600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol.]
Principal Investigator: John Thompson, MD
Study Number: 20132215
Phase: III

Safety Study of Anti-LAG-3 in CLL, HL and NHL

[Complete title: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas]
Principal Investigator: Ajay Gopal, MD
Study Number: 20132238
Phase: I

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC)

[Complete title: A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)]
Principal Investigator: Jennifer Specht, MD
Study Number: 20132296
Phase: III

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

[Complete title: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20132322
Phase: I

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

[Complete title: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer]
Principal Investigator: Evan Yu, MD
Study Number: 20140069
Phase: I

A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies

[Complete title: A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with MEDI4736 and MEDI0680 Monotherapy in Subjects with Select Advanced Malignancies]
Principal Investigator: Laura Chow
Study Number: 20140775
Phase: I

Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL

[Complete title: A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20141037
Phase: II

MSB0010718C in Subjects With Merkel Cell Carcinoma

[Complete title: A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel cell carcinoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20141039
Phase: II

Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)

[Complete title: A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20141655
Phase: I/II

A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

[Complete title: An Open-Label, Phase Ia/Ib/IIa Study of GDC-0810 Single Agent or in Combination with Palbociclib and/or an LHRH Agonist in Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer]
Principal Investigator: Hannah Linden, MD
Study Number: 20141791
Phase: I

A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

[Complete title: A Phase 1 Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer]
Principal Investigator: Laura Chow
Study Number: 20141860
Phase: I

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

[Complete title: A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA]
Principal Investigator: Edward Libby
Study Number: 20142069
Phase: I

ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies

[Complete title: A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects with B-cell Malignancies]
Principal Investigator: Stephen Smith
Study Number: 20142444
Phase: I/II

Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer

[Complete title: A Phase I Study of ES414 In Patients with Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20142613
Phase: I

A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors

[Complete title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTEDLOCALLY ADVANCED OR METASTATIC CARCINOMAS]
Principal Investigator: John Thompson, MD
Study Number: 20150061
Phase: I

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

[Complete title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20150094
Phase: I

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)

[Complete title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy (RANGE)]
Principal Investigator: Evan Yu, MD
Study Number: 20150398
Phase: III

Safety Study of SEA-CD40 in Cancer Patients

[Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies]
Principal Investigator: Andrew Coveler, MD
Study Number: 20150420
Phase: I

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7)

[Complete title: A Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges]
Principal Investigator: Christina Baik
Study Number: 20150427
Phase: II

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

[Complete title: A Phase I/II, open-label multi-center study to determine safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in patients with acute myeloid leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20150436
Phase: I/II

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

[Complete title: A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20150466
Phase: I

A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors

[Complete title: A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors]
Principal Investigator: Laura Chow
Study Number: 20150515
Phase: I

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

[Complete title: A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)]
Principal Investigator: Ryan Cassaday
Study Number: 20150518
Phase: I

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

[Complete title: Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients with Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 OR L858R +/- T790M) Non-Small Cell Lung Cancer]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20150645
Phase: I/II

The Vital Amyloidosis Study, a Phase 3, Multicenter Efficacy and Safety Study of NEOD001

[Complete title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled. 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis]
Principal Investigator: Edward Libby
Study Number: 20150681
Phase: III

Study of Neukoplast (NK-92) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)

[Complete title: Phase II Study of aNK (activated NK-92, formerly Neukoplast) Infusions in Patients with Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20150886
Phase: II

First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects with Relapsed or Refractory Acute Myeloid Leukemia]
Principal Investigator: Mary-Elizabeth Percival
Study Number: 20150973
Phase: I

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

[Complete title: Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20151071
Phase: II

Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

[Complete title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma]
Principal Investigator: Michi Shinohara
Study Number: 20151086
Phase: III

Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone

[Complete title: A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.]
Principal Investigator: Robert Montgomery, MD
Study Number: 20151131
Phase: II

Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer

[Complete title: A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women]
Principal Investigator: Hannah Linden, MD
Study Number: 20151217
Phase: II

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium

[Complete title: An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium]
Principal Investigator: Rafael Santana-Davila
Study Number: 20151222
Phase: I

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

[Complete title: A Phase I Study to Evaluate The Safety, PHarmacokinetics and PHarmacodynamics of Escalating Doses of a Vaccine-Based Immunotherapy Regimen (VBIR) for Prostate Cancer (PF-06753512)]
Principal Investigator: Tia Higano, MD
Study Number: 20151318
Phase: I

A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa

[Complete title: A phase 2 multi-center investigation of efficacy of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)]
Principal Investigator: Lee Cranmer
Study Number: 20151429
Phase: II

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

[Complete title: A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies]
Principal Investigator: Laura Chow
Study Number: 20151522
Phase: I

A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]

[Complete title: A Phase III, open-label, multicenter, randomized study of mpdl3280a (anti-pd-l1 antibody) versus observation as adjuvant therapy in patients with pd-l1-selected, high-risk muscle-invasive bladder cancer after cystectomy]
Principal Investigator: Michael Schweizer
Study Number: 20151596
Phase: III

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

[Complete title: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma]
Principal Investigator: Veena Shankaran
Study Number: 20151610
Phase: III

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

[Complete title: A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant.]
Principal Investigator: Stephen Smith
Study Number: 20151683
Phase: II

A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma

[Complete title: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma]
Principal Investigator: William Harris
Study Number: 20151721
Phase: I

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) With Peripheral T-Cell Lymphoma (PTCL)

[Complete title: A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) PLUS Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20151824
Phase: I

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)

[Complete title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment]
Principal Investigator: Lupe Salazar, MD
Study Number: 20151845
Phase: III

Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)

[Complete title: A Phase 1A/1B Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers]
Principal Investigator: John Thompson, MD
Study Number: 20151981
Phase: I

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

[Complete title: A Phase I/II open-label study to assess the safety, pharmacokinetics, and antitumor activity of oral EPI-506 in patients with metastatic castration-resistant prostate cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 20152018
Phase: I/II

A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374) (CheckMate 374)

[Complete title: A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Renal Cell Carcinoma]
Principal Investigator: Scott Tykodi, MD
Study Number: 20152079
Phase: III

An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

[Complete title: An Open-label Phase 1 Study of Oral ASP5878 at Single and Multiple Doses in Patients with Solid Tumors]
Principal Investigator: Robert Montgomery, MD
Study Number: 20152120
Phase: I

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

[Complete title: A Phase 3, Multicenter, Randomized, Open-Label Study of Avelumab (MSB0010718C) Alone or in Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone in Patients With Platinum-Resistant/Refractory Ovarian Cancer]
Principal Investigator: Nora Disis, MD
Study Number: 20152134
Phase: III

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

[Complete title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma]
Principal Investigator: John Thompson, MD
Study Number: 20152183
Phase: II

A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)

[Complete title: Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-963558) In subjects with Virus-Positive and Virus-Negative Tumors]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20152209
Phase: I/II

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

[Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements]
Principal Investigator: Gabriela Chiorean
Study Number: 20152369
Phase: II

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

[Complete title: STING (Study of Immunotherapy in Newly Diagnosed Glioblastoma): A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy]
Principal Investigator: Lynne Taylor, MD
Study Number: 20152376
Phase: III

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

[Complete title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma]
Principal Investigator: Andrew Coveler, MD
Study Number: 20152434
Phase: III

A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)

[Complete title: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression CheckMate 436: CHECKpoint pathway and nivolumab clinical Trail Evaluation]
Principal Investigator: Andrei Shustov, MD
Study Number: 20152441
Phase: I/II

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

[Complete title: A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination with Axitinib (Inlyta) versus Sunitinib (Sutent) Monotherapy in the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma]
Principal Investigator: Scott Tykodi, MD
Study Number: 20152576
Phase: III

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

[Complete title: AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY EVALUATING THE EFFICACY, SAFETY AND PHARMACOKINETICS OF ROVALPITUZUMAB TESIRINE (SC16LD6.5) FOR THIRD-LINE AND LATER TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY DELTA-LIKE PROTEIN 3-EXPRESSING SMALL CELL LUNG CANCER (TRINITY)]
Principal Investigator: Rafael Santana-Davila
Study Number: 20152704
Phase: II

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

[Complete title: Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects with Advanced Malignancies]
Principal Investigator: Ryan Cassaday
Study Number: 20152763
Phase: I

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

[Complete title: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers]
Principal Investigator: John Thompson, MD
Study Number: 20152783
Phase: I

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

[Complete title: A phase 1, open-label, dose-esclation study of SGN-CD19B in patients with relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma]
Principal Investigator: Stephen Smith
Study Number: 20160030
Phase: I

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer [IMpower 132]

[Complete title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN + PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN + PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND HAVE STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER]
Principal Investigator: Rafael Santana-Davila
Study Number: 20160241
Phase: III

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis (PRONTO)

[Complete title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001-201 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction.]
Principal Investigator: Edward Libby
Study Number: 20160284
Phase: II

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER)

[Complete title: monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician’s Choice plus Trastuzumab in Women with HR+, HER2+ Locally Advanced or Metastatic Breast Cancer]
Principal Investigator: Lupe Salazar, MD
Study Number: 20160464
Phase: II

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

[Complete title: A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors]
Principal Investigator: Gabriela Chiorean
Study Number: 20160524
Phase: I

Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)

[Complete title: BMS CA209-577 (CheckMate 577): A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer]
Principal Investigator: Veena Shankaran
Study Number: 20160534
Phase: III

Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors

[Complete title: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors]
Principal Investigator: Scott Tykodi, MD
Study Number: 20160860
Phase: I/II

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

[Complete title: A Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck]
Principal Investigator: Tina Rodriguez, MD
Study Number: 20160938
Phase: I/II

Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

[Complete title: An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20160970
Phase: II

A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma

[Complete title: A Phase 1b, Multicenter, Open-Label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma]
Principal Investigator: Stephen Smith
Study Number: 20160991
Phase: I

A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

[Complete title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)]
Principal Investigator: Laura Chow
Study Number: 20161065
Phase: II

Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

[Complete title: A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors]
Principal Investigator: Christina Baik
Study Number: 20161101
Phase: I/II

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

[Complete title: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20161383
Phase: I/II

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

[Complete title: A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides]
Principal Investigator: John Thompson, MD
Study Number: 20161740
Phase: I

Dose-escalation Study of BAY1129980

[Complete title: An open-label Phase I dose-escalation study to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-C4.4a antibody drug conjugate BAY 1129980 in subjects with advanced solid tumors known to express C4.4a]
Principal Investigator: Rafael Santana-Davila
Study Number: 20161858
Phase: I

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)

[Complete title: A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)]
Principal Investigator: Cristina Rodriguez
Study Number: 20161878
Phase: II

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

[Complete title: A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)]
Principal Investigator: Scott Tykodi, MD
Study Number: 20161907
Phase: II

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)

[Complete title: A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies]
Principal Investigator: Heather Cheng
Study Number: 20162044
Phase: II

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

[Complete title: ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer]
Principal Investigator: Elizabeth Swisher, MD
Study Number: 20162178
Phase: III

Study of RXDX-105 (RET and BRAF Inhibitor) in Patients With Advanced Solid Tumors

[Complete title: AN OPEN-LABEL, PHASE 1/1B, SINGLE-AGENT STUDY OF RXDX-105 IN PATIENTS WITH ADVANCED SOLID TUMORS]
Principal Investigator: Cristina Rodriguez
Study Number: 20162262
Phase: I

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy

[Complete title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY]
Principal Investigator: V.K. Gadi, MD, PhD
Study Number: 20162265
Phase: II

Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC)

[Complete title: A Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies]
Principal Investigator: Scott Tykodi, MD
Study Number: 20162312
Phase: I/II

A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC)

[Complete title: A Phase 2, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric)]
Principal Investigator: Veena Shankaran
Study Number: 20162429
Phase: II

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

[Complete title: Phase 1b, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589)]
Principal Investigator: Jennifer Specht, MD
Study Number: 20162431
Phase: I

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

[Complete title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma]
Principal Investigator: Evan Yu, MD
Study Number: 20162614
Phase: III

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)

[Complete title: A Phase 2, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)]
Principal Investigator: Scott Tykodi, MD
Study Number: 20162874
Phase: II

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

[Complete title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)]
Principal Investigator: Evan Yu, MD
Study Number: 20162991
Phase: I/II

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies

[Complete title: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects with Hematological Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 20170102
Phase: I/II

Phase 1/2A Dose Escalation Study in CLL, SLL or NHL

[Complete title: A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB (PRT062070) IN PATIENTS WITH RELAPSED/ REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/ SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL OR T-CELL NON-HODGKIN LYMPHOMA (NHL)]
Principal Investigator: Stephen Smith
Study Number: 20170188
Phase: I/II

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

[Complete title: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER]
Principal Investigator: Christina Baik
Study Number: 20170224
Phase: III

Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor

[Complete title: A PHASE IB, OPEN-LABEL STUDY OF THESAFETY AND TOLERABILITY OF ATEZOLIZUMAB IN COMBINATION WITH RADIUM-223 DICHLORIDE IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING TREATMENT WITH AN ANDROGEN PATHWAY INHIBITOR]
Principal Investigator: Tia Higano, MD
Study Number: 20170291
Phase: I

A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

[Complete title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma]
Principal Investigator: Edward Libby
Study Number: 2512.00
Phase: I

Low Dose Cytarabine and Lintuzumab-Ac225 in Older AML Patients

[Complete title: A Phase I/II Study of Lintuzumab-Actinium-225 in Older Patients with Untreated Acute Myeloid Leukemia (AML)]
Principal Investigator: Johnnie Orozco, MD, PhD
Study Number: 2572.00
Phase: I/II

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

[Complete title: A Study Evaluating BPX-501 T cells and AP1903 for Prevention of GVHD after HLA-Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2615.00
Phase: I/II

ety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

[Complete title: A Phase1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2653.00
Phase: I

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

[Complete title: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy]
Principal Investigator: William Harris
Study Number: 7627
Phase: III

GS-5806 in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

[Complete title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract]
Principal Investigator: Michael Boeckh, MD
Study Number: 9208
Phase: II

A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)

[Complete title: A Phase 1/2 Study of Venetoclax in Combination with Low-Dose Cytarabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are >= 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy]
Principal Investigator: Roland Walter, MD
Study Number: 9237
Phase: I/II

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

[Complete title: A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors]
Principal Investigator: Vivian Oehler, MD
Study Number: 9238
Phase: IV

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma

[Complete title: Feasibility of Assessing Drug Response to Precise Local Injection of Anti-Cancer Drugs Using Presage’s CIVO™ Device in Soft Tissue Sarcoma Patients Undergoing Surgery]
Principal Investigator: Seth Pollack
Study Number: 9260
Phase: Pilot

A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (WIRB#20142430)]
Principal Investigator: Seth Pollack
Study Number: 9290
Phase: I

Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant

[Complete title: Phase 1/2 Study of CaspaCide T Cells from an HLA-Partially Matched Family Donor after Negative Selection of TCR aß+ T Cells in Pediatric Patients Affected by Hematological Disorders]
Principal Investigator: Ann Woolfrey, MD
Study Number: 9311
Phase: I/II

A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

[Complete title: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia]
Principal Investigator: Roland Walter, MD
Study Number: 9382
Phase: I

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

[Complete title: A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination with Azacitidine in Patients with Myelodysplastic Syndromes]
Principal Investigator: Bart Scott, MD
Study Number: 9414
Phase: I

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

[Complete title: A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR]
Principal Investigator: Roland Walter, MD
Study Number: 9498
Phase: I/II

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

[Complete title: A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia or CD25-positive Acute Lymphoblastic Leukemia]
Principal Investigator: Roland Walter, MD
Study Number: 9513
Phase: I

Trial of CMB305 and Atezolizumab in Patients With Sarcoma (IMDZ-C232)

[Complete title: A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1]
Principal Investigator: Seth Pollack
Study Number: 9521
Phase: II

UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease

[Complete title: Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction With THERAKOS® CELLEX® Photopheresis Systems in Pediatric Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGvHD)]
Principal Investigator: Paul Carpenter, MD
Study Number: 9550
Phase: III

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

[Complete title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First Line Therapy in Subjects with Chronic Graft Versus Host Disease]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 9587
Phase: II

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ENHANCE)

[Complete title: Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC 122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma]
Principal Investigator: Mazyar Shadman
Study Number: 9597
Phase: I/II

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

[Complete title: A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 9643
Phase: II

Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA)

[Complete title: IOMAB-01: A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia]
Principal Investigator: Johnnie Orozco, MD, PhD
Study Number: 9645
Phase: III

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia

[Complete title: A phase 1 study of SGN-CD123A in patients with relapsed or refractory acute myeloid leukemia (AML)]
Principal Investigator: Roland Walter, MD
Study Number: 9653
Phase: I

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia (UNITY-CLL)

[Complete title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)]
Principal Investigator: Mazyar Shadman
Study Number: 9657
Phase: III

Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment

[Complete title: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-Assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir]
Principal Investigator: Joshua Hill
Study Number: 9663
Phase: III

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)

[Complete title: Phase II Study of Pembrolizumab (MK 3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)]
Principal Investigator: Mazyar Shadman
Study Number: 9672
Phase: II

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

[Complete title: A Phase 3, Multicenter, Randomized, Open-label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents]
Principal Investigator: Bart Scott, MD
Study Number: 9723
Phase: III

Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL

[Complete title: Phase I/II Study of Pembrolizumab in Combination with TG-1101 (Ublituximab) and TGR-1202 in Patients with Relapsed-Refractory CLL or Richter’s Transformation of CLL]
Principal Investigator: Mazyar Shadman
Study Number: 9727
Phase: I/II

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)

[Complete title: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory(R/R) B-cell Non-Hodgkin Lymphoma (NHL)]
Principal Investigator: David Maloney, MD, PhD
Study Number: 9734
Phase: I

A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma

[Complete title: Phase 1 study of SGN-CD352A in Patients with Relapsed or Refractory Multiple Myeloma]
Principal Investigator: Damian Green, MD
Study Number: 9736
Phase: I

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

[Complete title: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent]
Principal Investigator: Bart Scott, MD
Study Number: 9782
Phase: III

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: A Phase 2, Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid) in Pediatric Subjects from 1 to = 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia]
Principal Investigator: Doug Hawkins, MD
Study Number: AAML1522
Phase: II

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

[Complete title: ADVL1322, A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors]
Principal Investigator: Julie Park, MD
Study Number: ADVL1322
Phase: II

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

[Complete title: Dasatinib in Combination with Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia.]
Principal Investigator: Todd Cooper
Study Number: SC-2026
Phase: I

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

[Complete title: SC-4003, BRF116013, Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF V600-Mutation Positive Solid Tumors]
Principal Investigator: Sarah Leary
Study Number: SC-4003
Phase: I/II

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)

[Complete title: SC-4005: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)]
Principal Investigator: Erin Pinto
Study Number: SC-4005
Phase: I/II

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

[Complete title: SC-4007,EZH-102, A Phase I Study of the EZH2 Inhibitor Tazemtostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma]
Principal Investigator: Erin Pinto
Study Number: SC-4007
Phase: I

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

[Complete title: SC-4008, EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma]
Principal Investigator: Erin Pinto
Study Number: SC-4008
Phase: II

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients

[Complete title: SC-4011, A Post-Marketing Study to Further Assess the Immunogenicity and Safety of UnituxinTM in High-Risk Neuroblastoma Patients]
Principal Investigator: Julie Park, MD
Study Number: SC-4011
Phase: IV

Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors (SCOUT)

[Complete title: SC-4012, LOXO-TRK-15003, Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors]
Principal Investigator: Doug Hawkins, MD
Study Number: SC-4012
Phase: I

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

[Complete title: A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors]
Principal Investigator: Doug Hawkins, MD
Study Number: SC-6017
Phase: I

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

[Complete title: A Phase I and expanded imaging study of BLZ-100 in pediatric patients with primary central nervous system tumors]
Principal Investigator: Sarah Leary
Study Number: SC-9009
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials